Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial
I'm PortAI, I can summarize articles.
Innovent Biologics Inc. and Ollin Biosciences reported positive Phase 1b results for IBI324 in a clinical trial for diabetic macular edema and wet age-related macular degeneration. The study showed IBI324's superior outcomes compared to faricimab, with plans to advance to global Phase 3 studies. Full results will be presented at a symposium in February 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments